{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["66(7)"],"submitter":["Lilleby W"],"funding":["This study was supported by The Norwegian Research Council (FORNY program), Innovation Norway AS, Ultimovacs AS."],"pubmed_abstract":["In newly diagnosed metastatic hormone-naive prostate cancer (mPC), telomerase-based immunotherapy with the novel hTERT peptide vaccine UV1 can induce immune responses with potential clinical benefit. This phase I dose escalation study of UV1 evaluated safety, immune response, effects on prostate-specific antigen (PSA) levels, and preliminary clinical outcome. Twenty-two patients with newly diagnosed metastatic hormone-naïve PC (mPC) were enrolled; all had started androgen deprivation therapy and had no visceral metastases. Bone metastases were present in 17 (77%) patients and 16 (73%) patients had affected lymph nodes. Three dose levels of UV1 were given as intradermal injections combined with GM-CSF (Leukine<sup>®</sup>). Twenty-one patients in the intention-to-treat population (95%) rece"],"journal":["Cancer immunology, immunotherapy : CII"],"pagination":["891-901"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028648"],"repository":["biostudies-literature"],"pubmed_title":["Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer."],"pmcid":["PMC11028648"],"pubmed_authors":["Lilleby W","Inderberg EM","Mills K","Vlatkovic L","Hole KH","Gaudernack G","Brunsvig PF","Schulz M"],"additional_accession":[]},"is_claimable":false,"name":"Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.","description":"In newly diagnosed metastatic hormone-naive prostate cancer (mPC), telomerase-based immunotherapy with the novel hTERT peptide vaccine UV1 can induce immune responses with potential clinical benefit. This phase I dose escalation study of UV1 evaluated safety, immune response, effects on prostate-specific antigen (PSA) levels, and preliminary clinical outcome. Twenty-two patients with newly diagnosed metastatic hormone-naïve PC (mPC) were enrolled; all had started androgen deprivation therapy and had no visceral metastases. Bone metastases were present in 17 (77%) patients and 16 (73%) patients had affected lymph nodes. Three dose levels of UV1 were given as intradermal injections combined with GM-CSF (Leukine<sup>®</sup>). Twenty-one patients in the intention-to-treat population (95%) rece","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jul","modification":"2026-06-02T01:42:44.631Z","creation":"2026-04-13T03:12:17.806Z"},"accession":"S-EPMC11028648","cross_references":{"pubmed":["28391357"],"doi":["10.1007/s00262-017-1994-y"]}}